<DOC>
	<DOCNO>NCT02722590</DOCNO>
	<brief_summary>The objective post-marketing surveillance study observe safety profile Fycompa film-coated tablet 2/4/6/8/10/12 milligram ( mg ) normal clinical practice setting .</brief_summary>
	<brief_title>Post-Marketing Surveillance Study Fycompa Film-coated Tablets Korean Patients</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Participants approve indication Fycompa Korea : adjunctive therapy treatment partialonset seizure without secondarily generalize seizures participant epilepsy age 12 year old Participants write consent use personal medical information study purpose Hypersensitivity active substance excipients medicine Fycompa contains lactose ; therefore , participant rare hereditary problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption take medicine Other participant judge inadequate participate study doctor</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial-onset seizure</keyword>
	<keyword>secondarily generalize seizure</keyword>
</DOC>